It is proposed that measles-containing vaccines have immunomodulatory effects which include a reduction in all-cause childhood mortality. The antibody response to heterologous vaccines provides a means to explore these immunomodulatory effects. This is the first study to investigate the influence of measles-mumps-rubella (MMR) vaccine on the persistence of antibodies to a broad range of heterologous infant vaccinations given in the first year of life. In total, 319 children were included in the study. All infants received routine vaccinations at 6 weeks, 4 and 6 months of age. At 12 months of age, 212 children were vaccinated with MMR and Haemophilus influenzae type b-meningococcus C (Hib-MenC) vaccines while the remaining 99 children had not yet received these vaccines. In the MMR/Hib-MenC-vaccinated group, blood was taken 28 ± 14 days after receiving these vaccines. Antibodies against diphtheria, tetanus, pertussis [pertussis toxin (PT), filamentous hemagglutinin, pertactin], poliomyelitis (type 1, 2, 3) and 13 pneumococcal serotypes were measured. Seroprotection rates and geometric mean antibody concentrations were compared between MMR/MenC-Hib-vaccinated and MMR/MenC-Hib-naïve participants. In the final analysis, 311 children were included. Seroprotection rates were lower in MMR/Hib-MenC-vaccinated children against PT and pneumococcal serotype 19A. After adjustment for prespecified factors, MMR/Hib-MenC-vaccinated infants had significantly higher antibody concentrations against tetanus (likely explained by a boosting effect of the carrier protein, a tetanus toxoid), while for the other vaccine antigens there was no difference in antibody concentrations between the two groups. MMR vaccination given at 12 months of age in a developed country does not significantly influence antibody concentrations to heterologous vaccines received in the first year of life.

中文翻译：

---

麻疹-腮腺炎-风疹疫苗接种对异源疫苗反应持续性的免疫调节作用。

提出含麻疹的疫苗具有免疫调节作用，包括降低全因儿童死亡率。对异源疫苗的抗体应答提供了探索这些免疫调节作用的手段。这是第一项研究麻疹-腮腺炎-风疹（MMR）疫苗对出生后第一年给予的多种异源婴儿疫苗抗体持久性影响的研究。该研究总共包括319名儿童。所有婴儿均在6周，4和6个月大时接受常规疫苗接种。在12个月大时，有212名儿童接受了MMR和B型脑膜炎球菌C型流感嗜血杆菌疫苗的接种，而其余99名儿童尚未接种这些疫苗。在MMR / Hib-MenC疫苗接种组中，接种这些疫苗后28±14天采血。测量了针对白喉，破伤风，百日咳[百日咳毒素（PT），丝状血凝素，百日咳杆菌素]，脊髓灰质炎（1、2、3型）和13种肺炎球菌血清型的抗体。比较了接种过MMR / MenC-Hib和未接种MMR / MenC-Hib的参与者的血清保护率和几何平均抗体浓度。最终分析包括311名儿童。在接受MMR / Hib-MenC疫苗接种的儿童中，针对PT和肺炎球菌血清型19A的血清保护率较低。在调整了预先设定的因素后，接种MMR / Hib-MenC的婴儿对破伤风的抗体浓度明显更高（可能是由破伤风类毒素载体蛋白的增强作用引起的），对于其他疫苗抗原，两组之间的抗体浓度没有差异。在发达国家，在12个月大时进行MMR疫苗接种不会显着影响出生后第一年接受的异源疫苗的抗体浓度。